Free Trial
NASDAQ:KPTI

Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis

Karyopharm Therapeutics logo
$4.55 -0.45 (-9.00%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$4.34 -0.21 (-4.51%)
As of 07/11/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Karyopharm Therapeutics Stock (NASDAQ:KPTI)

Key Stats

Today's Range
$3.70
$4.58
50-Day Range
$4.12
$7.09
52-Week Range
$3.51
$16.95
Volume
1.74 million shs
Average Volume
83,905 shs
Market Capitalization
$39.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.40
Consensus Rating
Buy

Company Overview

Karyopharm Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

KPTI MarketRank™: 

Karyopharm Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 220th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Karyopharm Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Karyopharm Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Karyopharm Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($0.71) to ($0.43) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Karyopharm Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Karyopharm Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Karyopharm Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    25.50% of the float of Karyopharm Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Karyopharm Therapeutics has a short interest ratio ("days to cover") of 25.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Karyopharm Therapeutics has recently increased by 0.50%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Karyopharm Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Karyopharm Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    25.50% of the float of Karyopharm Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Karyopharm Therapeutics has a short interest ratio ("days to cover") of 25.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Karyopharm Therapeutics has recently increased by 0.50%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Karyopharm Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Karyopharm Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    4 people have searched for KPTI on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,585.00 in company stock.

  • Percentage Held by Insiders

    Only 2.98% of the stock of Karyopharm Therapeutics is held by insiders.

  • Percentage Held by Institutions

    66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Karyopharm Therapeutics' insider trading history.
Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KPTI Stock News Headlines

HC Wainwright Begins Coverage on Karyopharm Therapeutics (NASDAQ:KPTI)
Banks aren’t ready for this altcoin—are you?
The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change.
Karyopharm to Cut About 20% of Workforce Amid Ongoing Review
See More Headlines

KPTI Stock Analysis - Frequently Asked Questions

Karyopharm Therapeutics' stock was trading at $10.1445 at the beginning of the year. Since then, KPTI stock has decreased by 55.1% and is now trading at $4.55.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) released its quarterly earnings results on Monday, May, 12th. The company reported ($2.77) earnings per share for the quarter, topping the consensus estimate of ($4.21) by $1.44. The company had revenue of $30.02 million for the quarter, compared to analyst estimates of $35.12 million.
Read the conference call transcript
.

Shares of Karyopharm Therapeutics reverse split on Wednesday, February 26th 2025.The 1-15 reverse split was announced on Monday, February 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Karyopharm Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Enovix (ENVX), Tesla (TSLA), Globant (GLOB), Luminar Technologies (LAZR) and Rambus (RMBS).

Company Calendar

Last Earnings
5/12/2025
Today
7/13/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KPTI
CIK
1503802
Fax
N/A
Employees
380
Year Founded
N/A

Price Target and Rating

High Price Target
$75.00
Low Price Target
$10.00
Potential Upside/Downside
+722.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($13.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$76.42 million
Net Margins
-43.99%
Pretax Margin
-43.97%
Return on Equity
N/A
Return on Assets
-35.95%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.33
Quick Ratio
1.28

Sales & Book Value

Annual Sales
$145.24 million
Price / Sales
0.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($22.10) per share
Price / Book
-0.21

Miscellaneous

Outstanding Shares
8,640,000
Free Float
8,383,000
Market Cap
$39.31 million
Optionable
Optionable
Beta
0.24

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:KPTI) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners